Survival outcomes and patterns of failure in women with stage IIIC2 endometrial carcinoma

被引:9
作者
Lee, Joon K. [1 ]
Mahan, Meredith [2 ]
Hanna, Rabbie K. [3 ]
Elshaikh, Mohamed A. [1 ]
机构
[1] Henry Ford Hosp, Dept Radiat Oncol, 2799 West Grand Blvd, Detroit, MI 48202 USA
[2] Henry Ford Hosp, Dept Publ Hlth Sci, Detroit, MI 48202 USA
[3] Henry Ford Hosp, Dept Womens Hlth Serv, Div Gynecol Oncol, Detroit, MI 48202 USA
关键词
Endometrial carcinoma; Stage IIIC2; Advanced stage; Prognosis; Survival; Recurrence; POSTOPERATIVE RADIATION-THERAPY; PELVIC LYMPH-NODES; ADJUVANT CHEMOTHERAPY; AMERICAN SOCIETY; CANCER; RADIOTHERAPY; METASTASIS; MULTICENTER; SURGERY; TRIAL;
D O I
10.1016/j.ejogrb.2017.08.001
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Objectives: Para-aortic lymph node involvement in women with endometrial carcinoma (EC) is a poor prognostic factor. Many studies have included women with stage IIIC2 in cohorts of patients with advanced stage disease. The aim of this study was to analyze survival outcomes and patterns of failure in women with solely stage IIIC2 EC. Methods: We identified women with FIGO stage IIIC2 EC who underwent surgical staging at our institution. In addition to descriptive analyses of patient demographics, tumor characteristics, and adjuvant treatment received, univariate log-rank analyses and Cox regression multivariate analyses (MVA) were performed to identify predictors of recurrence-free (RFS), disease-specific (DSS) and overall survival (OS). Results: A total of 72 women were included in this study cohort. The median follow-up time was 43 months. The median number of positive para-aortic lymph nodes was one. Of the 61 women (84.7%) who received adjuvant therapy, 40 women (65.6%) received chemotherapy and radiation therapy (CRT), 17 women (27.9%) received chemotherapy alone (CT), and only 4 women (6.6%) received radiation therapy alone. Thirty-seven women (51.4%) experienced disease recurrence. Distant metastasis was the most common pattern of failure (73%). Five-year RFS, DSS, and OS were 48%, 51%, and 48%, respectively. Due to small study size, our exploratory multivariate analysis demonstrated that histologic grade was the only significant prognostic factor for DSS (p = 0.03) and OS (p = 0.02). The type of adjuvant therapy did not sustain its independent predictive significance for RFS, DSS and OS. Conclusions: Our findings suggest that almost half of women with stage IIIC2 can be cured with surgical staging and adjuvant therapies. The most common pattern of failure was distant metastasis calling for further optimization of systemic therapy. (C) 2017 Elsevier B.V. All rights reserved.
引用
收藏
页码:192 / 197
页数:6
相关论文
共 39 条
[1]  
[Anonymous], 2015, Obstet Gynecol, V125, P1006, DOI 10.1097/01.AOG.0000462977.61229.de
[2]  
[Anonymous], AM J CLIN ONCOL
[3]   Clinical outcome with adjuvant treatment of endometrial carcinoma using intensity-modulated radiation therapy [J].
Beriwal, Sushil ;
Jain, Sheena K. ;
Heron, Dwight E. ;
Kim, Hayeon ;
Gerszten, Kristina ;
Edwards, Robert P. ;
Kelley, Joseph L. .
GYNECOLOGIC ONCOLOGY, 2006, 102 (02) :195-199
[4]   Treatment related outcomes in high-risk endometrial carcinoma: Canadian high risk endometrial cancer consortium (CHREC) [J].
Bernardini, Marcus Q. ;
Gien, Lilian T. ;
Lau, Susie ;
Altman, Alon D. ;
Gilks, Blake ;
Ferguson, Sarah E. ;
Koebel, Martin ;
Samouelian, Vanessa ;
Wesa, Mina ;
Cameron, Anna ;
Nelson, Gregg ;
Han, Guangming ;
Clarke, Blaise ;
Ho, T. C. ;
Panzarella, Tony ;
Atenafu, Eshetu G. ;
McAlpine, Jessica N. .
GYNECOLOGIC ONCOLOGY, 2016, 141 (01) :148-154
[5]   Survival Analysis of Endometrial Cancer Patients With Positive Lymph Nodes [J].
Brown, Aaron P. ;
Gaffney, David K. ;
Dodson, Mark K. ;
Soisson, A. Pat ;
Belnap, Thomas W. ;
Alleman, Kerry ;
Sause, William T. .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (05) :861-868
[6]   Combined treatment with chemotherapy and radiotherapy in high-risk FIGO stage III-IV endometrial cancer patients [J].
Bruzzone, M ;
Miglietta, L ;
Franzone, P ;
Gadducci, A ;
Boccardo, F .
GYNECOLOGIC ONCOLOGY, 2004, 93 (02) :345-352
[7]   Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].
Colombo, N. ;
Preti, E. ;
Landoni, F. ;
Carinelli, S. ;
Colombo, A. ;
Marini, C. ;
Sessa, C. .
ANNALS OF ONCOLOGY, 2013, 24 :33-38
[8]   Carcinoma of the corpus uteri [J].
Creasman, W. T. ;
Odicino, F. ;
Maisonneuve, P. ;
Quinn, M. A. ;
Beller, U. ;
Benedet, J. L. ;
Heintz, A. P. M. ;
Ngan, H. Y. S. ;
Pecorelli, S. .
INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 95 :S105-S143
[9]   Toxicity and quality of life after adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): an open-label, multicentre, randomised, phase 3 trial [J].
de Boer, Stephanie M. ;
Powell, Melanie E. ;
Mileshkin, Linda ;
Katsaros, Dionyssios ;
Bessette, Paul ;
Haie-Meder, Christine ;
Ottevanger, Petronella B. ;
Ledermann, Jonathan A. ;
Khaw, Pearly ;
Colombo, Alessandro ;
Fyles, Anthony ;
Baron, Marie-Helene ;
Kitchener, Henry C. ;
Nijman, Hans W. ;
Kruitwagen, Roy F. ;
Nout, Remi A. ;
Verhoeven-Adema, Karen W. ;
Smit, Vincent T. ;
Putter, Hein ;
Creutzberg, Carien L. .
LANCET ONCOLOGY, 2016, 17 (08) :1114-1126
[10]   Influence of Comorbidity on the Risk of Death A Single Institution Study of 1132 Women With Early-stage Uterine Cancer [J].
Elshaikh, Mohamed A. ;
Vance, Sean ;
Kamal, Mona ;
Burmeister, Charlotte ;
Hanna, Rabbie K. ;
Rasool, Nabila ;
Siddiqui, Farzan .
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2017, 40 (02) :183-188